Costello-Boerrigter LC, Boerrigter G, Harty GJ, Cataliotti A, Redfield MM, Burnett JC (2007)
Mineralocorticoid escape by the kidney but not the heart in experimental asymptomatic left ventricular dysfunction
Hypertension, 50 (3), 481-8
PubMed
17635858 DOI
10.1161/HYPERTENSIONAHA.107.088534Heublein DM, Huntley BK, Boerrigter G, Cataliotti A, Sandberg SM, Redfield MM, Burnett JC (2007)
Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide
Hypertension, 49 (5), 1114-9
PubMed
17372040 DOI
10.1161/HYPERTENSIONAHA.106.081083Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, Burnett JC (2007)
Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure
Hypertension, 49 (5), 1128-33
PubMed
17325237 DOI
10.1161/HYPERTENSIONAHA.106.083832Huntley BK, Sandberg SM, Noser JA, Cataliotti A, Redfield MM, Matsuda Y, Burnett JC (2006)
BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors
J Cell Physiol, 209 (3), 943-9
PubMed
16986166 DOI
10.1002/jcp.20793Chen HH, Huntley BK, Schirger JA, Cataliotti A, Burnett JC (2006)
Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure
J Am Soc Nephrol, 17 (10), 2742-7
PubMed
16928803 DOI
10.1681/ASN.2006020161Belluardo P, Cataliotti A, Bonaiuto L, Giuffrè E, Maugeri E, Noto P, Orlando G, Raspa G, Piazza B, Babuin L, Chen HH, Martin FL, McKie PM, Heublein DM, Burnett JC, Malatino LS (2006)
Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy
Am J Physiol Heart Circ Physiol, 291 (4), H1529-35
PubMed
16648193 DOI
10.1152/ajpheart.00107.2006McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, Jacobsen SJ, Redfield MM, Burnett JC (2006)
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure
Hypertension, 47 (5), 874-80
PubMed
16585413 DOI
10.1161/01.HYP.0000216794.24161.8cChen HH, Schirger JA, Cataliotti A, Burnett JC (2006)
Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure
Eur J Heart Fail, 8 (7), 681-6
PubMed
16459135 DOI
10.1016/j.ejheart.2005.12.005Hawkridge AM, Heublein DM, Bergen HR, Cataliotti A, Burnett JC, Muddiman DC (2005)
Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure
Proc Natl Acad Sci U S A, 102 (48), 17442-7
PubMed
16293687 DOI
10.1073/pnas.0508782102Martin FL, Stevens TL, Cataliotti A, Schirger JA, Borgeson DD, Redfield MM, Luchner A, Burnett JC (2005)
Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure
Kidney Int, 67 (5), 1723-30
PubMed
15840018 DOI
10.1111/j.1523-1755.2005.00269.x